Table 1 |
|||
|
Demographic, clinical and laboratory data of systemic lupus erythematosus (SLE) patients at the time of the study |
|||
|
Active LN |
No active LN |
||
|
History of LN |
No history of LN |
||
|
|
|||
|
Total number |
21 |
15 |
33 |
|
Male/female, number |
4/17 |
3/12 |
2/31 |
|
Age, years, median (range) |
38 (16 to 53) |
46 (18 to 61) |
48 (20 to 81) |
|
SLEDAI, mean ± SD |
13.7 ± 3.7 ***,+++ |
2.7 ± 1.7 |
2.8 ± 2.7 |
|
Anti-dsDNA antibody, IU/ml, median (range) |
140 (3 to 1,000) **, + |
19 (3 to 432) |
20.5 (3 to 1000) |
|
C3, g/l, median (range) |
0.55 (0.27 to 1.13)***,++ |
0.93 (0.43 to 1.48) |
0.97 (0.31 to 11.4) |
|
C4 (g/l), median (range) |
0.08 (0.03- 0.3)*,+ |
0.16 (0.06 to 0.3) |
0.12 (0.02 to 1.04) |
|
CRP, mg/I, median (range) |
5 (5 to 121) |
5 ( 5 to 21) |
5 (5 to 33) |
|
eGFR, ml/min |
72 (24 to 142) |
81 (45 to 145) |
89 (31 to 140) |
|
Serum creatinine, µmol/l, median (range) |
75 (46 to 406) |
71 (51 to 126) |
62 (47 to 141) |
|
24-hr proteinuria, g/24hr |
1.5 (0.3 to 8.4)***,+++ |
0.3 (0.2 to 2.5) # # # |
0.0 (0.0 to 0.1) |
|
Urine creatinine, mmol/l, median (range) |
7.6 (0.6 to 21.3) |
4.3 (1.6 to 15.7) |
6.2 (0.7 to 14.9) |
|
With/without treatment, number |
12/9 |
13/2 |
21/12 |
|
Patients using prednisone, number (%), dose, mg/day, median (range) |
10 (47.6%) 7.5 (2.5 to 60) |
10 (66.6%) 10 (5 to 60) |
8 (24.2%) 5 (1.25 to 10) |
|
Patients taking hydroxychloroquine, number (%), dose, mg/day, median (range) |
8 (38%) 350 ( 200 to 600) |
2 (13.3%) 400 (400) |
14 (42.2%) 400 (200 to 600) |
|
Patients using azathioprine, number (%), dose, mg/day, median (range) |
3 (14.3%) 100 (75 to 150) |
7 (46.6%) 75 (50 to150) |
6 (18.2%) 125 (75 to 150) |
|
|
|||
|
+Indicates difference between active lupus nephritis (LN) patients and patients with no active LN but with history of LN (+P ≤ 0.05, ++P ≤ 0.005, +++P ≤ 0.0005). *Indicates difference between active and inactive SLE patients (*P = 0.05,**P ≤ 0.005, ***P ≤ 0.0005). #Indicates difference between patients without active LN but with history of LN and inactive SLE patients with no history of LN (#P = 0.05, ##P ≤ 0.005, ###P ≤ 0.0005). Anti-dsDNA: anti-double stranded DNA; C3: Complement 3; C4 Complement 4; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; SLEDAI: systemic lupus erythematosus disease activity index. |
|||
|
Abdulahad et al. Arthritis Research & Therapy 2012 14:R184 doi:10.1186/ar4015 |
|||
